Roivant in the news and media

Roivant sales rise but miss expectations in Q2

In its quarterly earnings report released Monday morning, Roivant Sciences said that sales rose from $4.3 million in the same quarter in 2022 to $21.6 million. The sum, however, fell short of analyst expectations of $24.5 million.

Roivant Sciences Fiscal First-Quarter Loss Narrows Less Than Expected as Costs Widen

Roivant Sciences' (ROIV) fiscal first-quarter results missed Wall Street's
estimates, as the biotechnology company logged an increase in its overall
operating costs.

Roivant Sciences Reports Steep Losses and Lighter-Than-Expected Sales

Roivant Sciences, a leading biotech stock founded by presidential
candidate Vivek Ramaswamy, announced significant losses and
lower-than-anticipated sales during the second quarter. This news is expected to cause a decline in ROIV stock.

Retail Outlook Lifts Wall Street Pre-Bell; Asia Down Europe Up

Roivant Sciences plans to report earnings pre-bell, among others.

Roivant CEO hints at more deals shaping up as key Immunovant data loom

Roivant Sciences has more potential asset deals in the works — after setting up two Vants around Pfizer assets in the past two years — and hopes to be talking about them in 2024, CEO Matt Gline told analysts on a quarterly earnings call on Monday morning.

Top Biotech Roivant, Formed By Vivek Ramaswamy, Reports Steep Losses, Light Sales

Top-notch biotech stock Roivant Sciences — founded by presidential candidate Vivek Ramaswamy — reported steep losses and lighter-than-expected sales on Monday. ROIV stock is likely to tumble.

Roivant Sciences reports higher-than-expected FQ1 loss

Roivant Sciences has released its financial results for the first quarter, falling short of analyst expectations.The company reported earnings per share (EPS) of ($0.38), which is $0.10 worse than what analysts had predicted at ($0.28). Revenue for the quarter reached $21.62 million, lower than the consensus estimate of $24.77M.

Roivant Sciences Ltd. 2023 Q1 - Results - Earnings Call Presentation

The following slide deck was published by Roivant Sciences Ltd. in conjunction with their 2023 Q1 earnings call. (Earnings presentation transcript)

Roivant Sciences earnings come in below Street estimates despite VTAMA sales growth

Roivant Sciences shares traded modestly higher after the inflammation and immunology-focused biopharmaceutical company reported fiscal first-quarter financial results that fell short of expectations for both earnings and sales.

Roivant Sciences reports higher-than-expected FQ1 loss

Roivant Sciences Ltd. has released its financial results for the first quarter, falling short of analyst expectations.

Roivant Sciences earnings missed by $0.10, revenue fell short of estimates

Roivant Sciences reported second quarter EPS of $-0.380, $0.10 worse than the analyst estimate of $-0.280. Revenue for the quarter came in at $21.62M versus the consensus estimate of $24.77M.

A deal? An asset sale? A launch? Everyone is watching next moves for Roivant, BridgeBio

What’s next for two of biotech’s once-cool, now-hot companies? Hot on the heels of critical data readouts, Roivant Sciences and BridgeBio Pharma are enjoying two of 2023’s most dramatic stock turnarounds, after their briefly-out-of-favor business models have turned up potential blockbuster drugs.

Biotech Hangout

A weekly discussion of all things biotech – breaking news, data deals and FDA actions – with a community of biotech industry leaders and experts.

Swelling losses haven't held back gains for Roivant Sciences (NASDAQ:ROIV) shareholders since they're up 156% over 1 year

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you pick the right business to buy shares in, you can make more than you can lose. Take, for example Roivant Sciences Ltd. (NASDAQ:ROIV). Its share price is already up an impressive 156% in the last twelve months.

Best Workplaces for Innovators 2023: Science and technology

Newly minted graduates who join the biotech company enter a two-year rotational program where they spend six months with four different teams in various functions across the dozen different companies within the Roivant portfolio.

Dealmaking Gives Biotechs Needed Financial Relief, But Deal Terms Are Under Pressure

Roivant Sciences Ltd. CEO Matt Gline said during the same panel discussion that as a company that often licenses or acquires external drug candidates, “the last couple of years has been one of the best
environments for that kind of dealmaking in history, frankly, because people have fewer options. And so, if you can be one of their options, you're in a privileged position.”

Roivant Sciences's Return on Invested Capital Insights

According to Benzinga Pro data, during Q4, Roivant Sciences posted sales of $27.38 million. Earnings were up 84.19%, but Roivant Sciences still reported an overall loss of $60.86 million. In Q3, Roivant Sciences brought in $17.05 million in sales but lost $384.90 million in earnings.

Analysts Just Made A Significant Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts

Roivant Sciences Ltd. (NASDAQ:ROIV) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's statutory forecasts. The consensus statutory numbers for both revenue and earnings per share (EPS) increased, with their view clearly much more bullish on the company's business prospects.

Is Roivant Sciences (ROIVW) a Winner in the Healthcare Sector?

Roivant Sciences (ROIVW) is around the top of the Healthcare sector according to InvestorsObserver. ROIVW received an overall rating of 78, which means that it scores higher than 78% of stocks. Additionally, Roivant Sciences scored a 71 in the Healthcare sector, ranking it higher than 71% of stocks in that sector.

Roivant Sciences GAAP EPS of -$0.20 beats by $0.18, revenue of $27.38M beats by $9.18M

Why Shares of Roivant Sciences Rose Wednesday

Roivant reported fourth-quarter revenue of $27.4 million, up 197% year over year, and an earnings per share (EPS) loss of $0.05, compared to an EPS loss of $0.39 in the same period a year ago. The improved EPS is really what propelled the stock higher.

Roivant Sciences Surprises Investors with Impressive Q4 Performance Leading to Stock Surge

On June 28, 2023, Roivant Sciences surprised investors with its impressive Q4 performance, leading to a surge in its stock prices. The company’s financial results for the fourth quarter and fiscal year ending March 31, 2022, revealed a net loss of $352.01 million, marking a 15.01% decline compared to the previous year. Despite this setback, Roivant Sciences managed to surpass analysts’ predictions, with earnings per share of -$1.78 over the past four quarters. The company’s Q4 loss was offset by a remarkable 44.56% increase in revenue, surpassing all expectations.

After 'transformative' year, Roivant aims to challenge bigger rivals in inflammation and immunology

Roivant shares gain more than 10% after narrower-than-expected quarterly loss. After surviving some turbulent market conditions in its first years as a public company, Roivant Sciences Ltd. ROIV, is taking on industry behemoths as it develops new treatments for ulcerative colitis, Crohn’s disease and other conditions.

Roivant Reports Positive Results in Phase II Ulcerative Colitis Trial

Thursday, Roivant Sciences announced positive results from a Phase IIb trial of a closely watched treatment for different kinds of inflammatory bowel disease. RVT-3101, a monthly subcutaneously administered anti-TL1A antibody, showed positive results in patients with moderate to severe ulcerative colitis.

Five things for pharma marketers to know: Friday, June 23, 2023

Roivant Sciences released Phase IIb data for RVT-3101, the UC program it acquired from Pfizer late last year, showing that the drug’s effects could be maintained for up to a year. It’s confirmation of earlier data showing success at 14 weeks — a statistically significant finding, Roivant said in January.

As Roivant readies for a UC clash with Merck, CEO Matt Gline is candid about keeping a competitive edge

Roivant CEO Matt Gline is getting ready for a development showdown with Merck and its newly acquired ulcerative colitis drug from Prometheus Biosciences.

Roivant rises after long-term data for ulcerative colitis candidate

Why Roivant Sciences Stock is Trading Higher Today

Roivant Sciences Ltd released results from the chronic period of the TUSCANY-2 Phase 2b study of RVT-3101 in adult patients with moderate to severe ulcerative colitis.

The company says this is the first-ever long-duration data reported for an anti-TL1A antibody.

Roivant reports more positive data for inflammation drug

Some analysts see the new results as further confirmation that Roivant’s medicine could become a blockbuster treatment for inflammatory bowel disease.

Roivant’s longer-term colitis data set a bar in emerging TL1A class

New Phase IIb ulcerative colitis data showing rising remission rates over time suggest a molecule from Roivant and Pfizer has exceeded efficacy expectations, driving a gain in market cap of about $334 million and setting a bar for others in the class.

Roivant Sciences shares gain after ulcerative colitis treatment shows longer-term results

Shares of Roivant Sciences Ltd. ROIV, 1.25% gained 14% in premarket trading Thursday after the company released new long-duration data from a study of its monoclonal antibody RVT-3101 in adults with ulcerative colitis. The treatment resulted in improved clinical remission of 36% at week 56, versus 29% at week 14, the company said in a release.

Why Roivant Sciences Stock Is Perking Up Today

Positive long-term data for a novel ulcerative colitis medication is fueling a double-digit rise in the drugmaker's stock.

Goldman Sachs Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

In a report released today, Corinne Jenkins from Goldman Sachs maintained a Buy rating on Roivant Sciences (ROIV – Research Report), with a price target of $14.00. The company’s shares opened today at $10.05.

Roivant Plots ‘Streamlined’ Phase III As Ulcerative Colitis Data Raise Blockbuster Potential

The company announced data from the Phase IIb TUSCANY-2 trial of RVT-3101, which is in a tight race with PRA023 from Prometheus, which Merck recently acquired for $10.8bn.

A First-Ever In Ulcerative Colitis Sends Roivant Stock Into A Breakout

"Our expectations for this chronic data were categorically exceeded with significant improvements seen in patients receiving the expected Phase 3 dose across all key (effectiveness) metrics at week 56 vs. at week 14," Roivant Chief Executive Matt Gline said in a written statement.

Roivant shares climb on longer-term ulcerative colitis drug results

Shares of Roivant Sciences were up 17% in premarket trade Thursday after the company released new longer-duration data from a Phase IIb study of RVT-3101 in adults with ulcerative colitis. "These results continue to support RVT-3101's potential as a first-in-class anti-TL1A antibody, demonstrating sustained efficacy across a broad dose range measured at 56 weeks," the company said.

Roivant rises on growing hopes for novel immunology mechanism

After impressive induction results in January, maintenance data from the same trial of Roivant’s RVT-3101 have increased excitement about the novel TL1A-targeting mechanism. Ulcerative colitis patients showed ongoing improvements on clinical and endoscopic remission endpoints in the phase 2b Tuscany-2 trial, with “compelling efficacy” across cohorts at 56 weeks; Roivant executives described the 36% endoscopic remission rate in biomarker-positive patients treated with the anticipated phase 3 dose as unparalleled.

Roivant Sciences: Financial Fortitude And Pipeline Advancements Demonstrate Strength

The breadth of Roivant's (NASDAQ:ROIV) product pipeline and the versatility of its business model substantiate its strength as a biopharmaceutical player. The success of VTAMA and the potential of RVT-3101, along with other promising products in late-stage clinical trials, underscore Roivant's dedication to pioneering healthcare solutions. Its robust financials and innovative research model further enhance its investment appeal. Hence, Roivant Sciences presents a compelling investment proposition for investors seeking to capitalize on cutting-edge therapeutics and a unique business approach in the biopharmaceutical sector.

Roivant Sciences: Coming Nicely To The Boil With Multiple Opportunities

Roivant's Pipeline & Products Suggest Blockbuster Revenues Await - & Perhaps Significantly More - A Strong, Albeit Higher Risk Investment Opportunity

Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old

Finger On The Pulse: The State Of Biopharma Leadership

In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.

Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?

Last December, Pfizer (NYSE: PFE) essentially out-licensed its tumor necrosis factor-like ligand 1A (TL1A), PF-06480605 (now RVT-3101), to Roivant Sciences (NASDAQ: ROIV) by forming a new company with the precision drugmaker. Per the terms of the deal Pfizer owns a 25% equity stake in the new company, along with the drug's commercial rights outside of the U.S. and Japan.

Small Molecule Immunotherapy

In the wake of the Covid-19 pandemic, there’s one issue that unites hospitals around the globe: health worker burnout. As part of its strategy to help its existing healthcare customers—and woo new ones—Amazon’s cloud division has selected 23 health tech startups from a pool of 500 applications to participate in its latest healthcare accelerator program focused on workforce issues.

Roivant’s Covant Therapeutics and BI join forces to explore covalent drug space

With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders.

Roivant Sciences has added another branch to its family tree, unveiling Covant Therapeutics with a $10 million upfront commitment from Boehringer Ingelheim to turn up the heat in cancer.

Roivant stock jumps as skin cream Vtama meets main goal of phase 3 eczema trial

Dermavant Sciences' Vtama cream met the main goal of achieving clearer skin in a phase 3 trial to treat patients as young as two years old, and adults with atopic dermatitis (AD).

Roivant’s stock rallies on new data for dermatitis drug

Roivant's Vtama Meets Key Endpoints in Atopic Dermatitis Study >ROIV

Roivan­t's ul­cer­a­tive col­i­tis drug from Pfiz­er shows promis­ing da­ta in ear­ly read­out

Roivant’s ulcerative colitis drug acquired from Pfizer last month has already produced positive data in the first readout of the Phase IIb trial.

Roivant Sciences: 'Fiercely Economic Actor' With Multiple Catalysts

Advancing Medicines That Matter, Matt Gline, CEO, Roivant Sciences

Matt Gline is the CEO of Roivant Sciences, a company that delivers innovative medicines and technologies to patients by building Vants – nimble, entrepreneurial biotech and healthcare technology companies.

Collecting Pharma’s Scraps Can Pay Off for This Biotech

Roivant Is Striving Towards New Standards Of Care

With numerous highly anticipated data readouts due over 2023, the spotlight is on Roivant like never before. CEO Matt Gline enlightens In Vivo on the firm’s ‘vant’ subsidiaries, its in-house drug development strategies and the future of its Vtama psoriasis treatment.

Matt Gline wants you to stop thinking of Roivant as a discard company. In 2023, he'll prove it

Matt Gline has had enough of the quips. Over the course of his seven-year tenure at Roivant Sciences—the last two as CEO—he's fended off what he thinks are condescending characterizations that the “vant” parent company is a discard-reliant pharma and prognostications about the potential of the drugs it works on.

Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant

Failure is part of building a biotech, and Roivant’s CEO says it provides a blueprint for managing scientifically risky bets. Roivant Sciences is hoping for a big year.

JPM23: Roivant CEO says 2023 shaping up to be 'single most exciting year' for new readouts

Much has been said about the tumultuousness of the biotech market in 2022 and how the industry and associated innovation will fare in the new year. Roivant Sciences CEO Matt Gline has heard the prognosticating and, at this year’s J.P. Morgan Healthcare Conference, he had a concise message on behalf of his company: We’re moving up.

Five things for pharma marketers to know: Thursday, January 5, 2023

Eli Lilly struck a $55 million deal with Capsida Biotherapeutics to develop gene therapies for central nervous system diseases. Under the agreement, Eli Lilly’s Prevail, which it acquired in 2021 to develop its gene therapy unit, will spearhead early development and Capsida will lead discovery.

Roivant Sciences Sees Positive Trial Results for RVT-3101 Antibody

Fresh from Pfizer deal, Roivant posts 'best-in-class' ulcerative colitis data on rival to Prometheus prospect

Roivant Sciences has shown its hand in the red-hot race for a new ulcerative colitis market. Weeks after Prometheus Biosciences wowed investors, and with the ink on its deal with Pfizer to enter the race still drying, Roivant has shared phase 2b data it claims position it as a best-in-class contender.

Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate

Roivant Sciences (NASDAQ: ROIV) announced results from the induction period of the TUSCANY-2 Phase 2b study of RVT-3101 (previously PF-06480605), a once-monthly anti-TL1A antibody for ulcerative colitis.

Roivant reports positive mid-stage data for ulcerative colitis therapy

U.K.-based biotech Roivant Sciences (NASDAQ:ROIV) announced Wednesday that its Phase 2b trial for subcutaneous ulcerative colitis therapy RVT-3101 generated statistically significant and clinically meaningful efficacy results at each dose level.

Roivant reveals positive data for IBD drug, intensifying rivalry with Prometheus

A race to develop a new kind of treatment for inflammatory bowel disease heated up Wednesday, with the release of positive data for an experimental drug that’s backed by Pfizer and Roivant Sciences.

Quick Takes: Roivant TL1A mAb heading into Phase III in ulcerative colitis

A Phase III showdown between anti-TL1A mAbs for ulcerative colitis is shaping up for 2023 with positive Phase IIb data for RVT-3101 from Roivant Sciences Ltd. (NASDAQ:ROIV) announced less than a month after Prometheus Biosciences Inc. (NASDAQ:RXDX) reported Phase II results for PRA023.

Roivant-Pfizer inflammatory bowel drug hits high expectations in mid-stage study

An experimental inflammatory bowel disease medicine that serves as the basis for a partnership between Roivant Sciences and Pfizer met high expectations for a Phase 2 clinical trial data released.

Pfizer Returns To Roivant As Development Partner For A Second Time